Modular Medical, Inc. (MODD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 10, 2025, details a material definitive agreement entered into by Modular Medical, Inc. The report covers a firm commitment underwritten public offering of common stock and warrants, with the transaction closing on December 11, 2025.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.68 million from the sale of Firm Shares and Firm Warrants.
- Securities Issued: 12,173,000 shares of Common Stock and warrants to purchase up to 6,086,500 shares.
- Offering Price: Combined price of $0.77 for two shares of Common Stock and one warrant.
- Effective Price: $0.38 per share and $0.01 per warrant.
- Underwriting Fees: 7% cash fee of gross proceeds plus reimbursement of expenses up to $85,000.
- Warrant Terms: Exercise price of $0.45 per share; exercisable immediately; expire five years from issuance.
- Over-Allotment Option: Underwriter granted a 30-day option to purchase up to 1,825,950 additional shares and/or warrants to purchase up to 912,975 additional shares (15% of the initial offering).
- Underwriter Warrant: Issued to the underwriter for 7% of shares sold (852,110 shares initially); exercise price at 120% of the offering exercise price ($0.54); 180-day lock-up on exercise.
Material Changes and Lock-Up Agreements
The filing does not provide comparative financial data (revenue, profit, or cash flow) as it reports a specific capital raising event rather than periodic financial results. Material changes include:
- Capital Structure: Significant increase in outstanding shares and potential dilution from the issuance of new stock and warrants.
- Liquidity: Immediate infusion of approximately $4.68 million in gross proceeds.
- Lock-Up Periods: Directors and executive officers are restricted from selling securities for 60 days. The Company is restricted from issuing or selling securities for 90 days.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, revenue projections, or management commentary regarding future operational performance. Key contingencies and risks identified include:
- Dilution: The issuance of shares and warrants will dilute existing shareholders.
- Over-Allotment: Additional dilution may occur if the underwriter exercises the 15% over-allotment option.
- Market Conditions: The success of the offering and future liquidity depend on market conditions and the ability to maintain an effective registration statement.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7% underwriting fee and the $85,000 expense cap.
- Confirm the exact number of shares issued if the 15% over-allotment option is exercised within the 30-day window.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and representations.
- Monitor the Company's cash burn rate to assess how long the $4.68 million in gross proceeds will extend the runway.
- Check for any subsequent filings regarding the exercise of the Underwriter Warrant after the 180-day restriction period.